Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities.

Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities.

Publication date: Feb 12, 2019

Studies of alternative RNA splicing (ARS) have the potential to provide an abundance of novel targets for development of new biomarkers and therapeutics in oncology, which will be necessary to improve outcomes for patients with cancer and mitigate cancer disparities. ARS, a key step in gene expression enabling individual genes to encode multiple proteins, is emerging as a major driver of abnormal phenotypic heterogeneity. Recent studies have begun to identify RNA splicing-related genetic and genomic variation in tumors, oncogenes dysregulated by ARS, RNA splice variants driving race-related cancer aggressiveness and drug response, spliceosome-dependent transformation, and RNA splicing-related immunogenic epitopes in cancer. In addition, recent studies have begun to identify and test, preclinically and clinically, approaches to modulate and exploit ARS for therapeutic application, including splice-switching oligonucleotides, small molecules targeting RNA splicing or RNA splice variants, and combination regimens with immunotherapies. Although ARS data hold such promise for precision oncology, inclusion of studies of ARS in translational and clinical cancer research remains limited. Technologic developments in sequencing and bioinformatics are being routinely incorporated into clinical oncology that permit investigation of clinically relevant ARS events, yet ARS remains largely overlooked either because of a lack of awareness within the clinical oncology community or perceived barriers to the technical complexity of analyzing ARS. This perspective aims to increase such awareness, propose immediate opportunities to improve identification and analysis of ARS, and call for bioinformaticians and cancer researchers to work together to address the urgent need to incorporate ARS into cancer biology and precision oncology.

Robinson, T.J., Freedman, J.A., Al Abo, M., Deveaux, A.E., LaCroix, B., Patierno, B.M., George, D.J., and , Patierno. Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities. 04401. 2019 Clin Cancer Res.

Concepts Keywords
Alternative Splicing SON
Biomarkers Alternative splicing
Cancer RNA splicing
Epitopes Spliceosome
Genetic Branches of biology
Immunogenic Gene expression
Immunotherapies Immunotherapies
Oligonucleotides
Oncogenes
Oncology
Preclinically
Sequencing
Splice Variants
Spliceosome
Splicing

Semantics

Type Source Name
gene UNIPROT CHL1
disease MESH community
pathway BSID Spliceosome
gene UNIPROT AMACR
disease MESH multiple
pathway BSID Gene Expression
gene UNIPROT PTPN5
disease MESH development
gene UNIPROT DCPS
gene UNIPROT SLURP1
disease DOID Cancer
disease MESH Cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *